TABLE 1.
Baseline characteristics
| Characteristics | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| LEN group (n = 182) | LIDA group (n = 118) | p value | LEN group (n = 78) | LIDA group (n = 78) | p value | |
| Age (y) | 49 ± 11 | 52 ± 11 | 0.072 | 51 ± 11 | 51 ± 10 | 0.933 |
| <50 (n, %) | 86 (47.3) | 47 (39.8) | 0.206 | 31 (39.7) | 33 (42.3) | 0.745 |
| ≥50 (n, %) | 96 (52.7) | 71 (60.2) | 47 (60.3) | 45 (57.7) | ||
| Gender (n, %) | 0.478 | 0.786 | ||||
| Male | 162 (89.0) | 108 (91.5) | 71 (91.0) | 70 (89.7) | ||
| Female | 20 (11.0) | 10 (8.5) | 7 (9.0) | 8 (10.3) | ||
| Body weight (kg) | 0.432 | 0.618 | ||||
| <60 (n, %) | 73 (40.1) | 42 (35.6) | 27 (34.6) | 30 (38.5) | ||
| ≥60 (n, %) | 109 (59.9) | 76 (64.4) | 51 (65.4) | 48 (61.5) | ||
| HBV (n, %) | 0.994 | 1.000 | ||||
| Absence | 20 (11.0) | 13 (11.0) | 11 (14.1) | 11 (14.1) | ||
| Presence | 162 (89.0) | 105 (89.0) | 67 (85.9) | 67 (85.9) | ||
| AFP (ng/ml) | 17,109 ± 86,562 | 69,225 ± 242,639 | 0.009 | 6759 ± 19,838 | 15,048 ± 42,787 | 0.122 |
| <400 | 96 (52.7) | 64 (54.2) | 0.800 | 48 (61.5) | 46 (59.0) | 0.744 |
| ≥400 | 86 (47.3) | 54 (45.8) | 30 (38.5) | 32 (41.0) | ||
| ECOG score (n, %) | 0.001 | 0.853 | ||||
| 0 | 150 (82.4) | 78 (66.1) | 59 (75.6) | 58 (74.4) | ||
| 1 | 32 (17.6) | 40 (33.9) | 19 (24.4) | 20 (25.6) | ||
| Child‐Pugh class | 0.007 | 0.667 | ||||
| A | 158 (86.8) | 88 (74.6) | 64 (82.1) | 66 (84.6) | ||
| B | 24 (13.2) | 30 (25.4) | 14 (17.9) | 12 (15.4) | ||
| Intrahepatic tumors number (n, %) | 0.669 | 0.565 | ||||
| Single | 36 (19.8) | 21 (17.8) | 19 (24.4) | 16 (20.5) | ||
| Multiple | 146 (80.2) | 97 (82.2) | 59 (75.6) | 62 (79.5) | ||
| Main tumor size (cm, %) | 8.0 ± 4.0 | 8.0 ± 4.8 | 0.911 | 7.6 ± 4.0 | 8.2 ± 5.1 | 0.395 |
| <5 | 45 (24.7) | 36 (30.5) | 0.270 | 22 (28.2) | 24 (30.8) | 0.725 |
| ≥5 | 137 (75.3) | 82 (69.5) | 56 (71.8) | 54 (69.2) | ||
| VI (n, %) | 0.078 | 0.585 | ||||
| Yes | 147 (80.8) | 85 (72.0) | 56 (71.8) | 59 (75.6) | ||
| No | 35 (19.2) | 33 (28.0) | 22 (28.2) | 19 (24.4) | ||
| EHS (n, %) | 0.008 | 0.873 | ||||
| Yes | 66 (36.3) | 57 (48.3) | 37 (47.4) | 38 (48.7) | ||
| No | 116 (63.7) | 61 (51.7) | 41 (52.6) | 40 (51.3) | ||
Abbreviations: AFP, alpha‐fetoprotein; ECOG, Eastern Cooperative Oncology Group (performance status); EHS, extrahepatic spread; HBV, hepatitis B virus; LIDA group, patients treated with lenvatinib plus idarubicin‐loaded drug‐eluting beads transarterial chemoembolization; LEN group, patients treated with lenvatinib alone; PSM, propensity score matching; VI, vascular invasion.